Sponsored Content

Assurance of Global Pharma Supply

Olon’s strategy for being resilient in times of instability.

Company Logo

Released By Olon Spa

What is the emerging geopolitical scenario, and what effects does it have on global and interconnected pharmaceutical supply chains? The COVID-19 pandemic undeniably marked the start of a new era of “polycrisis,” characterized by continuous, frequent, and devastating crises.
 
Olon—a leading active pharmaceutical ingredient (API) supplier headquartered in Italy and with a global manufacturing network comprising 11 production sites and 7 research centers worldwide—has discovered the key to transforming crises into opportunities and making its complex operational model resilient and flexible: diversification and a multi-center approach.
 
The mantra in supply chain management, according to Olon Group’s head of global strategic planning and supply chain, Cristiano Capriotti, has long been reduce, reduce, reduce.




“Reduce costs, reduce production centers, reduce the number of suppliers, and reduce stocks of raw materials,” he said. “However, this pursuit of leanness has also brought with it the risk of diminished resilience, reducing the extra capacity of the production system, pushing the ‘just-in-time’ approach to extremes, and forcing the system on decreasing costs and strategic options. This has centralized production in a handful of large hubs of maximized production and distribution, with substantial long-term investments, to achieve maximum efficiency.”
 

But being lean does not always allow you to be responsive to the market, particularly in situations of continued instability, such as we are experiencing today and will continue to experience for some time, according to Capriotti.
 
“Historically—not just since the crisis—at Olon we have seen the elimination of suppliers as a decrease in the company’s wealth and in the ability of being agile and responsive,” he explained. “Through great investment from the entire organization, including regulatory, QA, R&D, and operations sectors, we have pursued a structured Assurance of Supply program based on continuous risk analysis and the diversification of geopolitical areas of suppliers, and keeping European suppliers whenever possible. We have adhered to the principle of not being dependent on one single region, which can cause unforeseen problems and supply disruption, such as the closure of connecting channels or global political happenings affecting the circulation of goods that we are seeing today.”


 
Capriotti says Olon’s mantra against this has been a multi-center approach.
 
“We have pursued a strategy of incremental, decentralized, and multifunctional investments in all 11 sites around the world,” he said. “In the immediate term, it has certainly entailed higher costs. In the long term, it promises resilience and minimizes the risk of our operating system collapsing due to external factors. We have invested our systems to make them interchangeable, in our technologies to make them interoperable, and today we are able to provide customers with a global system response, rather than a single site response, and to react swiftly to fluctuating demand. This translates into great elasticity, flexibility, and speed.”
 
In certain cases, Olon has doubled the production capacity for high-demand products at very competitive times in the market. Capriotti concluded, “Today, the best choice is the one that leaves more options open for you because your system never stops. Our strategy has proven to be an asset.”

Learn more at www.olonspa.com

Request more information from Olon Spa

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters